AstraZeneca's Lynparza slows advanced breast cancer progression -study

June 4 (Reuters) - Women with advanced breast cancer who carry specific genetic mutations experienced double the response rate and delayed disease progression when treated with AstraZeneca Plc's Lynparza compared with standard chemotherapy, according to data from a late-stage trial presented on Sunday.

by reutersCOMPANYNEWS via Endless Supplies .Biz - News